NAFLD/MASH Cell Models and Lipotoxicity

A monoculture models one of three compartments, and fibrosis is not it.

Three compartments, one of which is easy to model

MASH is a tissue-level disease with three compartments. A monoculture contains one of them.

CompartmentWhat it contributesModelled by
ParenchymalSteatosis, ballooning, hepatocellular injuryHepatocyte monoculture
Non-parenchymalInflammation, stellate activation, fibrosisCo-culture or conditioned medium
SystemicSubstrate supply, insulin, adipose-derived fatty acidsAbsent in any dish

Important distinction. A monoculture can generate steatosis and a form of lipotoxic injury. It cannot generate fibrosis, because fibrosis is produced by activated stellate cells laying down matrix. A paper reporting "MASH model" on the basis of triglyceride accumulation and LDH release has modelled the first compartment only, and the name should say so.

Which hepatocyte

ModelMetabolic fidelityBest used forMain limitation
HepG2Low; tumour-derived, glycolytic, low CYP and low albuminConvenience screensRetains fetal-like metabolism; poor insulin response
Huh7Low–moderateReporter assays, some lipid workSimilar limitations; heterogeneous
Primary human hepatocyteHigh initiallyShort-term mechanistic workDedifferentiates within days; scarce
iPSC-derived hepatocyteModerate; improvingGenotype-defined, patient-specific questionsFetal-like; immature drug metabolism
Hepatocyte–NPC co-culture / organoidHigher, with architectureFibrosis and inflammation claimsCost, reproducibility, throughput

Caveat on immortalised lines. HepG2 and Huh7 are selected for proliferation, and proliferation and hepatocyte metabolic function are partly opposing programmes. The same selection that makes them convenient removes much of the metabolic phenotype being studied. A result that depends on gluconeogenic or lipogenic flux in HepG2 should be confirmed in a primary or iPSC-derived system before it is generalised.

Caveat on primary cells. Dedifferentiation is rapid: albumin and CYP expression fall within 48–72 hours in conventional monolayer. A 5-day treatment protocol in primary hepatocytes is therefore measuring a partially dedifferentiated cell, and the phenotype may reflect that transition rather than the treatment.

The fatty acid ratio is the design decision

CompositionDominant outcomeWhat it models
Oleate aloneTriglyceride storage, large droplets, little toxicitySteatosis without injury
Palmitate aloneER stress, apoptosis, small dropletsLipotoxicity, not steatosis
Oleate : palmitate 2:1Storage with modest injuryThe common "MASH" induction
Oleate : palmitate 1:1IntermediateHigher injury, less storage
Saturated + free cholesterolCholesterol crystal formation, inflammasomeA specific sub-phenotype

The ratio is not a technical detail; it determines which disease feature appears. Oleate is efficiently esterified and stored; palmitate is poorly esterified relative to its flux and is routed into ceramide, DAG and ER stress. Adding oleate therefore protects against palmitate toxicity while increasing triglyceride — the same paradox the disease pillar describes, reproduced in a dish.

Important distinction. Total triglyceride and toxicity move in opposite directions across this series. A compound that lowers triglyceride in a 2:1 model may be doing so by blocking esterification, which increases the free fatty acid and DAG pools. The measured improvement would then be the mechanism of harm.

Readouts, and what each one actually reports

ReadoutReportsDoes not report
Triglyceride mass (colorimetric)Total esterified lipidSpecies, compartment, toxicity
BODIPY 493/503Neutral lipid area and droplet countLipid species; may report droplet size only
Oil Red ONeutral lipid, endpointDynamics; requires fixation
LipidomicsSpecies compositionFlux; a static snapshot
LDH releaseMembrane integrityWhich death programme
Caspase-3/7Apoptotic executionFerroptosis or pyroptosis
CHOP, XBP1sER stress responseWhether ER stress is the cause of death
TG secretion (apoB, VLDL)Export capacityHepatic retention, which is the difference

Readout note. The last row is the one that distinguishes MASH from simple steatosis at the cellular level: retention is what happens when synthesis and uptake exceed export and oxidation. A model that increases triglyceride without measuring export has not shown retention.

Timing

Steatosis accumulates over 24–48 hours in most protocols; injury markers rise at 48–72 hours; inflammatory and fibrotic readouts need days to weeks and a co-culture. A 6-hour palmitate exposure is a biophysics experiment about membrane saturation, not a disease model, and reporting it as an MASH model mislabels the timescale.

Caveat on "ballooning". Ballooning degeneration is a histological diagnosis that depends on cell swelling, cytoskeletal redistribution and three-dimensional architecture. Two-dimensional culture can produce enlarged, lipid-laden cells, but calling them ballooned hepatocytes asserts a histological category that the system cannot establish.

The fibrosis boundary

If the claim involves fibrosis, the model needs stellate cells.

ComponentRequirementReadout
Stellate cell sourceLX-2 (immortalised) or primary human HSCα-SMA, COL1A1
ActivationCo-culture with lipid-loaded hepatocytes, or conditioned mediumα-SMA protein, not transcript alone
Matrix deposition3D or long-term co-cultureHydroxyproline, second-harmonic imaging
ArchitectureOrganoid or precision-cut sliceBridging septa — rarely achieved in vitro

Important distinction. α-SMA expression marks activation, not fibrosis. Fibrosis is matrix deposition with architectural change. Most in vitro systems can reach activation; few reach deposition; almost none reach architecture. A claim about "anti-fibrotic" activity from a 2D co-culture is a claim about stellate activation.

Failures that recur

  • • Palmitate-only protocol described as a steatosis model. It is an injury model.
  • • Triglyceride used as the efficacy endpoint. It can fall while toxicity rises.
  • • No viability-normalised lipid measurement. Fewer cells can look like less fat per well but more per cell.
  • • BSA concentration unreported. Free fatty acid concentration depends on the molar ratio, not the nominal concentration.
  • • Two-day treatment called chronic. MASH develops over years.
  • • HepG2 used for an insulin-sensitivity claim. The line has weak insulin responsiveness and low hepatic function.
  • • Fibrosis inferred from a monoculture. No stellate cells, no matrix.

Where this connects

  • • Lipid pillar supplies the species logic: total triglyceride is the least informative measurement, and esterification is protective.
  • • Disease pillar supplies the readout frame: steatosis, activity and fibrosis are three separate claims with three separate readouts.
  • • Glucose pillar supplies the lipogenic substrate link: high glucose and insulin drive de novo lipogenesis, which is why "glucolipid" protocols combine them.
  • • Operationally, the protocol parameters — seeding, fatty acid preparation, refresh schedule, QC gates — are in the companion article on building a hepatocyte lipid droplet model.

Scientific interpretation and experimental design

  • • Name the compartment. A monoculture models parenchymal disease only.
  • • The fatty acid ratio is the experiment. Oleate stores, palmitate injures.
  • • Triglyceride is not the endpoint. Measure species and export.
  • • Normalise lipid to cell number. Otherwise toxicity reads as less fat.
  • • Report BSA molar ratio. Nominal fatty acid concentration is not free concentration.
  • • Ballooning is histological. Two-dimensional culture cannot establish it.
  • • Fibrosis needs stellate cells and matrix. α-SMA is activation, not fibrosis.

Selected references for further reading

  • • Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24:908–922.
  • • Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
  • • Listenberger LL, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. PNAS. 2003;100:3077–3082.
  • • Ricchi M, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. Journal of Gastroenterology and Hepatology. 2009;24:830–840.
  • • Febbraio MA, et al. Preclinical models for studying NASH-driven HCC: how useful are they? Cell Metabolism. 2019;29:18–26.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: